In addition to its glucose-lowering effects, several studies, including the ongoing EMPACT-MI trial (46) and DAPA-MI trial (47), have demonstrated a positive cardiovascular protective effect of SGLT2 inhibitors in non-DM patients. The gene discussed is SLC5A2; the disease is diabetes mellitus.